This activity is expired and is no longer available for CME credit.


Beyond the Burden: New Options and Regimens for the Treatment of Neovascular Age-related Macular Degeneration

Author(s)/Faculty: Peter K. Kaiser, MD; Carl D. Regillo, MD, FACS
Release Date: 4/5/2019Expiration Date: 4/4/2020
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of age-related macular degeneration (AMD), but it has introduced new problems—notably, the burden of treatment created by frequent intraocular injections. Continuing research on the use of different treatment regimens, together with the impending emergence of new anti-VEGF treatment options, offer clinicians opportunities to optimize AMD therapy by creating a balance between reducing treatment frequency and achieving and maintaining improvements in visual acuity. In this continuing medical education activity, expert faculty assess new dosing and administration schedules as well as interpret new clinical findings regarding the safety and efficacy of therapies in late-stage development for the management of patients with neovascular AMD.